AVM Biotechnology is a Seattle-based company developing a stand-alone technology ‘AVM0703’ to induce remission in relapsed/refractory lymphocytic blood cancer and solid tumor patients and as an immune reset therapy for autoimmune diseases like MS & T1D. AVM0703 can also be used as a safe pre-conditioning regimen. It has a lymphodepletion profile comparable to chemotherapy, including a direct therapeutic killing activity and is being positioned to replace chemotherapeutic/lymphodepleting agents.